Open
Actively Recruiting
Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer
About
Brief Summary
This phase II trial studies how well stereotactic body radiation therapy with HyperArc software technology works in treating patients with head and neck cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Histologically confirmed recurrent head and neck cancer; either unresectable or status post salvage surgery.
- History of radiation therapy for head and neck cancer with minimum 50% overlap of the 50% isodose line from prior treatment to the proposed treatment volume.
- Estimated life expectancy > 12 weeks.
- Karnofsky performance status >= 70 (Eastern Cooperative Oncology Group [ECOG] 0-2).
- Maximum tumor, or tumor bed, diameter < 5 cm.
- If a woman is of childbearing potential, a negative serum pregnancy test must be documented. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study participation and for up to 4 weeks following the study treatment.
- Ability to understand and willingness to sign a written informed consent.
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-001247
Category
Head and Neck Cancer
Principal Investigator
Contact
Location
- UCLA Westwood